Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 2/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.50 |
| ▸ | IL1RN | P18510 | 1/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92603 | 0.93 | PSMB5 (0.51) | PSMB5 | |
| SCHEMBL92779 | 0.89 | PSMB5 (0.49) | BIRC2PSMB5IL1RNERAP2ERAP1 | |
| SCHEMBL84943 | 0.89 | CAPN1 (0.54) | BIRC2PSMB5IL1RNERAP2ERAP1 | |
| SCHEMBL2605636 | 0.85 | BIRC2 (0.55) | BIRC2PSMB5IL1RNERAP2ERAP1 | |
| SCHEMBL85103 | 0.85 | ALDH1A1 (0.58) | BIRC2PSMB5CAPN1ALDH1A1THRB | |
| SCHEMBL84540 | 0.84 | BIRC2 (0.54) | BIRC2PSMB5IL1RNERAP2ERAP1 | |
| SCHEMBL13893311 | 0.84 | BIRC2 (0.54) | BIRC2PSMB5IL1RNERAP2ERAP1 | |
| SCHEMBL19474595 | 0.84 | BIRC2 (0.54) | BIRC2PSMB5IL1RNERAP2ERAP1 | |
| SCHEMBL85542 | 0.82 | YAP1 (0.53) | BIRC2PSMB5CAPN1ALDH1A1THRB | |
| SCHEMBL92794 | 0.82 | PSMB5 (0.52) | PSMB5IL1RNERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324174-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8207124-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207297-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207126-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207125-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207127-B2 | Compounds for enzyme inhibition | ONYX TECHNOLOGIES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120101050-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101048-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120094930-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094928-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094926-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8129346-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-7491704-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080200398-A1 | Compounds For Enzyme Inhibition | PROTEOLIX, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7232818-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| WO-2005105827-A2 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200398-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | BIRC2 707/4885PSMB5 24/4885IL1RN 193/4885 |
| US-20120094928-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | BIRC2 707/4885PSMB5 24/4885IL1RN 193/4885 |
| US-20120094926-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | BIRC2 707/4885PSMB5 24/4885IL1RN 193/4885 |
| US-20120094930-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | BIRC2 707/4885PSMB5 24/4885IL1RN 193/4885 |
| US-20120101048-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | BIRC2 707/4885PSMB5 24/4885IL1RN 193/4885 |
| US-20120101050-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | BIRC2 707/4885PSMB5 24/4885IL1RN 193/4885 |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, PSMB1 | BIRC2 805/4885PSMB5 21/4885IL1RN 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.